{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:05:43Z","timestamp":1789725943805,"version":"4.0.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Use of 13-valent pneumococcal conjugate vaccine (PCV13) has reduced the burden of pneumococcal disease among both children and adults. Research has indicated that some population subgroups have benefited more than others. This study estimated rates of inpatient all-cause pneumonia among US adults by age, race, comorbidity profile, and household income (HHI), before and after universal recommendation for PCV13 in children and targeted recommendation for use in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective observational study was conducted using Optum's de-identified Clinformatics Data Mart Database (2007\u20132019). Adults aged \u226518 years were stratified by age, race, comorbidity profile (low-risk, at-risk\/high-risk), and annual household income. Inpatient all-cause pneumonia episodes were identified via relevant International Classification of Diseases (Ninth and Tenth Revisions) codes. Rates per 100 000 person-years and incidence rate ratios (IRRs) were calculated for the pre-PCV13 (2008\u20132009), peri-PCV13 (2010\u20132012), post-PCV13#1 (2013\u20132016), and post-PCV13#2 (2017\u20132019) periods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 38.7 million US adults, inpatient all-cause pneumonia rates decreased from the pre-PCV13 to post-PCV13#2 period among all age groups (eg, 72.9 to 38.2 among 18- to 49-year-olds and 1621.8 to 1326.0 among \u226575-year-olds). Irrespective of age, rates generally decreased from the pre-PCV13 to post-PCV13#2 period within subgroups defined by race, comorbidity profile, and HHI; the greatest relative reductions were observed among persons aged 18\u201349 years. During the post-PCV13#2 period, the highest rates of inpatient all-cause pneumonia persisted in Black adults, at-risk\/high-risk adults, and adults with HHI &amp;lt;$100 000.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite reductions in inpatient all-cause pneumonia following pediatric PCV13 introduction, residual disparities persist for Black, at-risk\/high-risk, and low- and middle-income adults. Strategies to reduce persistent disparities in disease burden among affected adults should be considered and implemented.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag528","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:47:28Z","timestamp":1787226448000},"source":"Crossref","is-referenced-by-count":0,"title":["Residual Disparities in US Adults Hospitalized due to All-Cause Pneumonia Following Implementation of Childhood 13-Valent Pneumococcal Conjugate Vaccine in National Immunization Program"],"prefix":"10.1093","volume":"13","author":[{"given":"Mark H","family":"Rozenbaum","sequence":"first","affiliation":[{"name":"Pfizer Inc HTA Value & Evidence, , Capelle A\/d Ijssel ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4490-7021","authenticated-orcid":false,"given":"Ahuva","family":"Averin","sequence":"additional","affiliation":[{"name":"Avalere Health Evidence & Strategy, , Washington, District of Columbia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Weycker","sequence":"additional","affiliation":[{"name":"Avalere Health Evidence & Strategy, , Washington, District of Columbia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4398-1588","authenticated-orcid":false,"given":"Rotem","family":"Lapidot","sequence":"additional","affiliation":[{"name":"Rambam Health Care Campus Division of Infectious Diseases, , Haifa ,","place":["Israel"]},{"name":"Israel Institute of Technology Faculty of Medicine, Technion, , Haifa ,","place":["Israel"]},{"name":"Boston Medical Centre Department of Pediatrics, , Boston, Massachusetts ,","place":["United States"]},{"name":"Boston University Chobanian & Avedisian School of Medicine Department of Pediatrics, , Boston, Massachusetts ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6486-6896","authenticated-orcid":false,"given":"Amanda","family":"Miles","sequence":"additional","affiliation":[{"name":"Pfizer Inc Real World Evidence and Epidemiology, , New York, New York ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6088-451X","authenticated-orcid":false,"given":"Maria J","family":"Tort","sequence":"additional","affiliation":[{"name":"Pfizer Inc US Vaccines Medical Affairs, , Collegeville, Pennsylvania ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8958-1734","authenticated-orcid":false,"given":"Paula","family":"Peyrani","sequence":"additional","affiliation":[{"name":"Pfizer Inc US Vaccines Medical Affairs, , Collegeville, Pennsylvania ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5610-3098","authenticated-orcid":false,"given":"Jeffrey","family":"Vietri","sequence":"additional","affiliation":[{"name":"Pfizer Inc HTA Value & Evidence, , Collegeville, Pennsylvania ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Lonshteyn","sequence":"additional","affiliation":[{"name":"Avalere Health Evidence & Strategy, , Washington, District of Columbia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen I","family":"Pelton","sequence":"additional","affiliation":[{"name":"Boston Medical Centre Department of Pediatrics, , Boston, Massachusetts ,","place":["United States"]},{"name":"Boston University Chobanian & Avedisian School of Medicine Department of Pediatrics, , Boston, Massachusetts ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"2026091805322660700_ofag528-B1","author":"Centers for Disease Control and Prevention"},{"key":"2026091805322660700_ofag528-B2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12913-016-1432-4","article-title":"Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions","volume":"16","author":"Weycker","year":"2016","journal-title":"BMC Health Serv Res"},{"key":"2026091805322660700_ofag528-B3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s12879-018-3326-z","article-title":"Clinical and economic burden of pneumococcal disease in US adults aged 19\u201364 years with chronic or immunocompromising diseases: an observational database study","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2026091805322660700_ofag528-B4","first-page":"540","article-title":"Racial disparities in adult pneumococcal vaccination indications and pneumococcal hospitalizations in the U.S","volume":"111","author":"Nowalk","year":"2019","journal-title":"J Natl Med Assoc"},{"key":"2026091805322660700_ofag528-B5","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/infdis\/jiaa515","article-title":"Marked reduction of socioeconomic and racial disparities in invasive pneumococcal disease associated with conjugate pneumococcal vaccines","volume":"223","author":"Raman","year":"2021","journal-title":"J Infect Dis"},{"key":"2026091805322660700_ofag528-B6","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.2105\/AJPH.2009.181313","article-title":"Socioeconomic and racial\/ethnic disparities in the incidence of bacteremic pneumonia among US adults","volume":"100","author":"Burton","year":"2010","journal-title":"Am J Public Health"},{"issue":"RR-9","key":"2026091805322660700_ofag528-B7","first-page":"1","article-title":"Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"49","author":"Advisory Committee on Immunization Practices","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"2026091805322660700_ofag528-B8","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"key":"2026091805322660700_ofag528-B9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"key":"2026091805322660700_ofag528-B10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1056\/NEJMoa1209165","article-title":"U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination","volume":"369","author":"Griffin","year":"2013","journal-title":"N Engl J Med"},{"key":"2026091805322660700_ofag528-B11","first-page":"1","article-title":"Prevention of pneumococcal disease among infants and children\u2014use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Advisory Committee on Immunization Practices","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026091805322660700_ofag528-B12","first-page":"816","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"61","author":"Advisory Committee on Immunization Practices","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026091805322660700_ofag528-B13","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Advisory Committee on Immunization Practices","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026091805322660700_ofag528-B14","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.15585\/mmwr.mm7239a5","article-title":"ACIP updates: recommendations for use of 20-valent pneumococcal conjugate vaccine in children\u2014United States, 2023","volume":"72","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026091805322660700_ofag528-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.mm7401a1","article-title":"Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged \u226550 years: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024","volume":"74","author":"Kobayashi","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026091805322660700_ofag528-B16","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/infdis\/jiw222","article-title":"Persistent sex disparities in invasive pneumococcal diseases in the conjugate vaccine era","volume":"214","author":"de St Maurice","year":"2016","journal-title":"J Infect Dis"},{"key":"2026091805322660700_ofag528-B17","doi-asserted-by":"crossref","first-page":"100384","DOI":"10.1016\/j.focus.2025.100384","article-title":"Uptake of pneumococcal vaccines among U.S. adults after 2022 update to recommendations","volume":"4","author":"Averin","year":"2025","journal-title":"AJPM Focus"},{"key":"2026091805322660700_ofag528-B18","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/cid\/ciy800","article-title":"Decline in pneumococcal disease attenuated in older adults and those with comorbidities following universal childhood PCV13 immunization","volume":"68","author":"Pelton","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026091805322660700_ofag528-B19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(14)70032-3","article-title":"Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis","volume":"2","author":"Simonsen","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026091805322660700_ofag528-B20","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1186\/s12913-018-3529-4","article-title":"Trends in healthcare utilization and costs associated with pneumonia in the United States during 2008\u20132014","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"2026091805322660700_ofag528-B21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/cid\/cix850","article-title":"Impact of pneumococcal vaccination on pneumonia hospitalizations and related costs in Ontario: a population-based ecological study","volume":"66","author":"Luca","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026091805322660700_ofag528-B22","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1183\/09031936.00183614","article-title":"Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia","volume":"45","author":"Rodrigo","year":"2015","journal-title":"Eur Respir J"},{"key":"2026091805322660700_ofag528-B23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/JAA.S200492","article-title":"Pneumonia in young adults with asthma: impact on subsequent asthma exacerbations","volume":"12","author":"Pelton","year":"2019","journal-title":"J Asthma Allergy"},{"key":"2026091805322660700_ofag528-B24","doi-asserted-by":"crossref","first-page":"ofv020","DOI":"10.1093\/ofid\/ofv020","article-title":"Rethinking risk for pneumococcal disease in adults: the role of risk stacking","volume":"2","author":"Pelton","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2026091805322660700_ofag528-B25","doi-asserted-by":"crossref","first-page":"ofu024","DOI":"10.1093\/ofid\/ofu024","article-title":"Rates of pneumococcal disease in adults with chronic medical conditions","volume":"1","author":"Shea","year":"2014","journal-title":"Open Forum Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag528\/70772280\/ofag528.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag528\/70772280\/ofag528.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag528\/70772280\/ofag528.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:33:18Z","timestamp":1789723998000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag528\/8769624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag528","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,24]]},"article-number":"ofag528"}}